Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.

Donakonda S, Sinha S, Dighe SN, Rao MRS.

Mol Biosyst. 2017 Jul 25;13(8):1481-1494. doi: 10.1039/c6mb00851h.

PMID:
28742165
2.

POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.

Ishii J, Sato H, Sakaeda M, Shishido-Hara Y, Hiramatsu C, Kamma H, Shimoyamada H, Fujiwara M, Endo T, Aoki I, Yazawa T.

Pathol Int. 2013 Mar;63(3):158-68. doi: 10.1111/pin.12042.

PMID:
23530560
3.

Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.

Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald P, Fairchild C, Wong T, Wee S.

Mol Cancer Ther. 2015 Oct;14(10):2167-74. doi: 10.1158/1535-7163.MCT-15-0037. Epub 2015 Aug 7.

4.

ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus.

Improgo MR, Schlichting NA, Cortes RY, Zhao-Shea R, Tapper AR, Gardner PD.

Mol Cancer Res. 2010 Feb;8(2):194-203. doi: 10.1158/1541-7786.MCR-09-0185. Epub 2010 Feb 2.

5.

Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.

Fujino K, Motooka Y, Hassan WA, Ali Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi H, Kubota I, Wakimoto J, Suzuki M, Ito T.

Am J Pathol. 2015 Dec;185(12):3164-77. doi: 10.1016/j.ajpath.2015.08.018. Epub 2015 Oct 23.

PMID:
26482608
6.

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.

Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93. doi: 10.1073/pnas.1410419111. Epub 2014 Sep 29.

7.

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.

Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, Girard L, Minna JD, Gazdar AF, Cobb MH, Johnson JE.

Cell Rep. 2016 Aug 2;16(5):1259-1272. doi: 10.1016/j.celrep.2016.06.081. Epub 2016 Jul 21.

8.

Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.

Ito T, Kudoh S, Ichimura T, Fujino K, Hassan WA, Udaka N.

Hum Cell. 2017 Jan;30(1):1-10. doi: 10.1007/s13577-016-0149-3. Epub 2016 Oct 26. Review.

PMID:
27785690
9.

Targeting the bHLH transcriptional networks by mutated E proteins in experimental glioma.

Beyeler S, Joly S, Fries M, Obermair FJ, Burn F, Mehmood R, Tabatabai G, Raineteau O.

Stem Cells. 2014 Oct;32(10):2583-95. doi: 10.1002/stem.1776.

10.

Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.

Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, Nelkin BD, Ball DW.

Cancer Res. 2009 Feb 1;69(3):845-54. doi: 10.1158/0008-5472.CAN-08-2762. Epub 2009 Jan 27.

11.

YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.

Horie M, Saito A, Ohshima M, Suzuki HI, Nagase T.

Cancer Sci. 2016 Dec;107(12):1755-1766. doi: 10.1111/cas.13078. Epub 2016 Nov 25.

12.

Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.

Takakuwa O, Maeno K, Kunii E, Ozasa H, Hijikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, Niimi A.

Lung Cancer. 2013 Aug;81(2):174-9. doi: 10.1016/j.lungcan.2013.04.022. Epub 2013 May 23.

PMID:
23706418
13.

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, Heukamp LC, Buettner R.

Int J Cancer. 2016 Feb 15;138(4):927-38. doi: 10.1002/ijc.29835. Epub 2015 Sep 25.

14.

Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer.

Yazawa T, Sato H, Shimoyamada H, Okudela K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, Ishii J, Miyata C, Sakaeda M, Goto K, Kashiwagi K, Masuda M, Takahashi T, Kitamura H.

Am J Pathol. 2009 Sep;175(3):976-87. doi: 10.2353/ajpath.2009.081004. Epub 2009 Aug 13.

15.

Achaete-scute complex homolog-1 promotes DNA repair in the lung carcinogenesis through matrix metalloproteinase-7 and O(6)-methylguanine-DNA methyltransferase.

Wang XY, Jensen-Taubman SM, Keefe KM, Yang D, Linnoila RI.

PLoS One. 2012;7(12):e52832. doi: 10.1371/journal.pone.0052832. Epub 2012 Dec 26.

16.

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.

Huang YH, Klingbeil O, He XY, Wu XS, Arun G, Lu B, Somerville TDD, Milazzo JP, Wilkinson JE, Demerdash OE, Spector DL, Egeblad M, Shi J, Vakoc CR.

Genes Dev. 2018 Jul 1;32(13-14):915-928. doi: 10.1101/gad.314815.118. Epub 2018 Jun 26.

17.

Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.

Chen C, Breslin MB, Lan MS.

Cell Signal. 2018 Jun;46:83-91. doi: 10.1016/j.cellsig.2018.02.014. Epub 2018 Mar 1.

PMID:
29501727
18.

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.

Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V.

BMC Syst Biol. 2013;7 Suppl 5:S1. doi: 10.1186/1752-0509-7-S5-S1. Epub 2013 Dec 9.

19.

Targeting SIM2-s decreases glioma cell invasion through mesenchymal--epithelial transition.

Su Y, Wang J, Zhang X, Shen J, Deng L, Liu Q, Li G.

J Cell Biochem. 2014 Nov;115(11):1900-7. doi: 10.1002/jcb.24859.

PMID:
24909296
20.

Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.

Westerman BA, Neijenhuis S, Poutsma A, Steenbergen RD, Breuer RH, Egging M, van Wijk IJ, Oudejans CB.

Clin Cancer Res. 2002 Apr;8(4):1082-6.

Supplemental Content

Support Center